In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Biotech GmbH

Division of Neopharm Ltd.
www.fresenius-biotech.com

Latest From Fresenius Biotech GmbH

Amgen’s Bispecific Blinatumomab May Be Ready For Leukemia Filing

Single-arm, Phase II data in relapsed acute lymphoblastic leukemia could suffice, firm says, for what would be the first-ever U.S. approval of an engineered bispecific antibody.

BioPharmaceutical Clinical Trials

Amgen’s Bispecific Blinatumomab May Be Ready For Leukemia Filing

Single-arm, Phase II data in relapsed acute lymphoblastic leukemia could suffice, firm says, for what would be the first-ever U.S. approval of an engineered bispecific antibody.

Clinical Trials Business Strategies

Deals Shaping The Medical Industry, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (03/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Fresenius Biotechnology
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Neopharm Ltd.
  • Senior Management
  • Christian Schetter, Pres. & CEO
    Alexander Dettmer, EVP, Fin. & Bus. Dev.
    Diane Seimetz, EVP, Pharmaceutical Drug Dev.
  • Contact Info
  • Fresenius Biotech GmbH
    Phone: (49)
    Frankfurter Ring 193a
    Munich, 80807
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register